Senolytics
Senolytics eliminate senescent cells that accumulate with age and drive systemic inflammation via the SASP. Cellular senescence is a formally recognized hallmark of aging (Lopez-Otin et al., 2013). The leading human research combination, dasatinib plus quercetin (D+Q), was identified at Mayo Clinic and has reached Phase 1 and 2 trials in specific age-related conditions. Unity Biotechnology is the primary clinical-stage company in the field. No senolytics are FDA-approved for aging, and no Atlas clinic currently offers them. The mechanistic foundation is among the strongest in aging biology; human outcome data remains early. Evidence tier: experimental.
What it is
Senolytics are pharmacological agents designed to selectively eliminate senescent cells, cells that have undergone permanent cell cycle arrest and ceased to divide but remain metabolically active, secreting a pro-inflammatory protein cocktail known as the senescence-associated secretory phenotype (SASP). Senescent cell accumulation in tissues is one of the formally recognized hallmarks of aging, established in the landmark Lopez-Otin et al. framework published in Cell in 2013, and the SASP is understood to drive systemic chronic low-grade inflammation, termed inflammaging, that contributes to dysfunction across multiple organ systems over time. The biological rationale for senolytics is direct: if senescent cells drive tissue dysfunction and the SASP is a measurable inflammatory output, selectively removing them should reduce local and systemic inflammatory burden and improve tissue function. The leading senolytic combination studied in human research is dasatinib, a tyrosine kinase inhibitor used in cancer treatment, plus quercetin, a common dietary flavonoid, abbreviated D+Q. This combination was identified as a senolytic by researchers at Mayo Clinic and has proceeded to Phase 1 and Phase 2 human trials, including in patients with idiopathic pulmonary fibrosis and diabetic kidney disease, with preliminary feasibility and efficacy signals published. As of mid-2026, no senolytics are FDA-approved for aging indications, no standard clinical protocol exists outside of trial settings, and the field remains in early-stage human translation. The animal data is mechanistically compelling and the human research is actively progressing, but translation to meaningful clinical outcomes in aging humans has not yet been demonstrated at sufficient scale.
Who it is for
Current evidence is limited to trial populations: patients with specific age-related conditions including idiopathic pulmonary fibrosis and diabetic kidney disease have been enrolled in early human trials, and early efficacy signals have been reported in these populations. There is no established clinical use outside of trial settings. Healthy older adults as a preventive longevity population are the long-term target of the field's hypothesis, but this application remains speculative pending adequate human trial data. Unity Biotechnology has pursued condition-specific indications rather than general aging as its regulatory strategy.
What to expect
Outside of clinical trial enrollment, senolytics are not an available clinical protocol. Researchers investigating D+Q have used intermittent dosing schedules, for example three consecutive days per month, based on the pharmacological rationale that a short burst of senolytic activity eliminates senescent cells without requiring continuous drug exposure. In trial settings, this is typically administered orally and monitored with blood biomarkers including circulating SASP proteins, inflammatory cytokines, and p16 expression in peripheral blood cells as a senescent cell burden proxy. No compounding pharmacy or clinic protocol for senolytics in healthy individuals has established clinical validity. Individuals inquiring about senolytics outside of trials are currently in a position where no evidence-supported clinical pathway exists.
History and background
The senolytic concept emerged from the aging biology field's work on cellular senescence, first described by Leonard Hayflick in 1961 in the context of replicative limits in cultured cells. The SASP was characterized in detail by Judith Campisi's laboratory at the Buck Institute over the following decades. The identification of D+Q as a senolytic combination by James Kirkland, Tamara Tchkonia, and colleagues at Mayo Clinic, published in 2015, was the field's first demonstration that pharmacological senescent cell clearance was achievable and associated with functional improvements in aged mice. The Lopez-Otin hallmarks framework in 2013 formalized cellular senescence as a recognized driver of aging, substantially elevating the field's credibility within mainstream biogerontology. Unity Biotechnology, founded in 2011 and backed by substantial venture investment, has been the leading company translating senolytic biology into clinical drug development, focusing initially on specific age-related conditions rather than general aging indications.
Worth knowing
Dasatinib, one half of the leading D+Q senolytic combination, was developed as a cancer drug for chronic myeloid leukemia and carries a known adverse effect profile at therapeutic cancer doses. The senolytic rationale uses it at lower doses and intermittently, but its repurposing from oncology to aging medicine illustrates a broader pattern in the longevity field: existing approved drugs being investigated at modified doses for aging indications. The SASP includes interleukin-6 and other cytokines that are also elevated in COVID-19 cytokine storm and other inflammatory conditions, connecting senescence biology to broader immunological research programs. Quercetin, the other half of D+Q, is available without prescription as a dietary supplement, and some individuals have independently combined it with physician-prescribed dasatinib outside of trial settings, a practice without clinical validation.
Related modalities